Circulating tumour DNA testing: Increasing access to cancer testing in Canada

Oncology patients have been heavily impacted by the ongoing SARS-CoV-2 pandemic. With thousands of tissue biopsies being delayed and patients postponing clinic visits, increasing access to Circulating tumour DNA (ctDNA) testing for targeted treatment selection offers another option for academic and community hospitals.

Canexia Health and Illumina invite you to watch this virtual discussion with a panel of experts. In this session you will learn:

  • How the pandemic caused delays in screening and diagnosis of new cancer patients
  • The impact of delayed cancer testing and late stage diagnosis
  • Using liquid biopsy to detect actionable variants
  • How liquid biopsy can alleviate the need for tissue biopsy and hospital visits
  • The feasibility of implementing ctDNA testing
  • How to continue driving ctDNA adoption beyond the pandemic


  • David Huntsman, MD, FRCPC, FCCMG
  • Harriet Feilotter, PhD, FCCMG
  • Sandeep Sehdev, MD, FRCPC
  • Xiaofu Zhu, MD, FRCPC
  • Melissa Brierley, PhD